Welcome to the Shen Lab

What is Pulmonary Arterial Hypertension?

Pulmonary Arterial Hypertension (PAH) is characterized by pulmonary vascular remodeling, or increased thickness of lung arteries. The remodeled pulmonary artery led to increased pulmonary arterial pressure and right ventricular afterload, leading to right heart failure.

PAH affects around 1 in 1,000 people, with the prevalence increasing in people over 65. While there are treatments to alleviate some of the symptoms, such as shortness of breath and chest pain, there is limited access to the cure for PAH - the reverse of pulmonary vascular remodeling. The Shen Lab aims to obtain a better understanding of the molecular mechanism of pulmonary vascular remodeling in PAH and, thereafter, develop potential pharmacological interventions. 

Our current projects consist of:

1. Understanding the molecular mechanism of Adult PAH

2. Understanding pediatric pulmonary hypertension developed due to congenital diaphragmatic hernia

Looking to get involved in research as an undergraduate?

Check out the Binghamton University Projects for New Undergraduate Researchers (BUPNUR) for a funded research opportunity. No research experience is necessary to apply. Applications close November 14th. 

Meet Yuanjun Shen

Assistant Professor of Pharmaceutical Sciences,  Principal Investigator

Binghamton University School of Pharmacy and Pharmaceutical Sciences

Pharmacy Building, Room 421

96 Corliss Ave

Johnson City NY

Dr. Yuanjun “Steve” Shen joined the Department of Pharmaceutical Sciences at Binghamton University in 2025. Shen Lab's research is funded by the NIH NHLBI K99/R00 Pathway to Independence Award, and mainly focuses on the mechanisms and pharmacological intervention of Pulmonary Hypertension. Read more about the lab's current projects.